快速但不愤怒:作为优化多发性硬化症患者管理策略的战略,快速输注ocrelizumab
Chiara Zanetta1, Patricia Faustino2, Simone Guerrieri1
1Neurology Unit and MS Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Journal of the neurological sciences
|January 26, 2024
概括
在多发性硬化症患者中,快速输注ocrelizumab (OCR-RI) 是安全有效的. 这种优化疗法可以减少输液时间,而不会增加输液相关反应,从而改善患者管理.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 多发性硬化症 (MS) 管理需要创新的治疗方法,以优化临床资源.
- 奥克雷利祖马布 (OCR) 是一种有效的MS疗法,通常通过标准输液 (OCR-SI) 给药.
研究的目的:
- 在多发性硬化症 (pwMS) 患者中评估ocrelizumab快速输液协议 (OCR-RI) 的安全性和有效性.
- 评估OCR-RI对输液相关反应 (IRR) 的影响,并将其与标准输液 (OCR-SI) 进行比较.
主要方法:
- 一个单一中心的研究比较OCR-RI (2.0小时) 与OCR-SI (3.5小时) 在pWMS中接受OCR-SI至少一年.
- 在OCR-RI和OCR-SI组之间对IRR频率,严重程度和管理进行比较分析.
主要成果:
- 在369名患者中,有283人过渡到OCR-RI. 没有过渡的主要原因是之前的输液相关反应或治疗时间不足.
- 输液相关反应频率 (在OCR-RI中为8.8%,在OCR-SI中为15.1%) 和严重程度在两组之间是可比的 (p=0.106).
- 快速输注ocrelizumab并没有被确定为输注相关反应的危险因素 (OR 0.55).
结论:
- 对ocrelizumab的快速输液协议是优化临床环境中患者管理的可行策略.
- 包括IRR频率和严重程度在内的OCR-RI的安全概况与OCR-SI相似.
- 在快速输液方案期间没有观察到严重的输液相关反应.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
120
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
120
Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
COPD: Management Using Bronchodilators and Corticosteroids
207
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
207


